Prorenata Labs LLC

Prorenata Labs LLC was paid $1.75M by Medicaid between Dec 2018 and Dec 2024, across 23 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 80% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Arizona

Rank by total paid#17 of 67

Median peer was paid$89K

This provider vs. median20×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	46	$3K
2019	1,031	$49K
2020	14,026	$298K
2021	14,527	$711K
2022	12,446	$556K
2023	3,328	$89K
2024incomplete	3,405	$47K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	80%	18,698	16,263	$1.41M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	5.3%	5,628	4,078	$93K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	3.1%	4,525	2,810	$55K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	3.0%	1,391	962	$52K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	2.0%	1,804	1,606	$36K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.0%	4,256	3,539	$35K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	1.1%	1,574	1,336	$19K
87481		<1%	1,410	958	$15K
87631		<1%	879	676	$12K
87500		<1%	1,410	961	$4K
87641		<1%	1,391	957	$4K
87581		<1%	997	747	$3K

11 more codes

87541		<1%	964	$3K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	958	$3K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	124	$3K
87640		<1%	1,324	$2K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	58	$1K
87653		<1%	283	$658.40
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	282	$641.94
87511		<1%	273	$641.94
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	283	$641.94
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	270	$514.24
87486		<1%	27	$116.97

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWILHOIT, DAN (VICE PRESIDENT)